The OJC Episode 35: Sugary Drinks, Chernobyl and Meaningful Consumer Engagement

Pinterest LinkedIn Tumblr +

The Oncology Podcast, brought to you by Oncology News Australia, is proud to present Episode 35 in our series The Oncology Journal Club.

Do you think sugary drinks could be responsible for the increased rates of colorectal cancer that we are seeing in young adults? Join us this week as Hans Prenen finds out.

Craig Underhill talks us through the TITAN Study and the problem of not acknowledging investigators. And Eva Segelov talks to Kristi Milley about getting meaningful engagement from consumers.

You’ll also hear the amazing article of the week on Chernobyl and climate change, the final installment of Eva’s Manifesto for Good Trial Design and some wonderfully quirky quick bites too.

About The Oncology Journal Club:

We have taken an old concept and updated it with a new format. In each episode a team of expert contributors will review topical journal papers and interview special guests who are leaders in their fields to help keep you informed of the latest developments on the go.

With The Oncology Podcast – and The Oncology Journal Club in particular – we are aiming to deliver oncology news differently,” Rachael Babin, Editor-in-Chief, Oncology News.

The Oncology Journal Club is hosted by Professor Eva Segelov, from Monash University. Eva is joined by Dr Craig Underhill from Albury-Wodonga and Professor Hans Prenen from Antwerp, Belgium. We hope you enjoy listening and find this a valuable and entertaining resource.


This Week’s Interview:

Milley K, et al. Long-term consumer involvement in cancer research: Working towards partnership. Health Expect. 2021 May 5. doi: 10.1111/hex.13258. Epub ahead of print. PMID: 33949071. Access online here.

This Week’s Papers:

  1. Chi, K.N., et al. Apalutamide in Patients With Metastatic Castration-Sensitive Prostate Cancer: Final Survival Analysis of the Randomized, Double-Blind, Phase III TITAN Study. Journal of Clinical Oncology. DOI: 10.1200/JCO.20.03488, published online April 29, 2021. Access online here.
  2. Murphy N, et al. Are sugar-sweetened beverages contributing to the rising occurrence of colorectal cancer in young adults? Gut. 2021 May 20:gutjnl-2021-324614. doi: 10.1136/gutjnl-2021-324614. Epub ahead of print. PMID: 34016645. Access online here.
  3. Gyawali B, et al. Biases in study design, implementation, and data analysis that distort the appraisal of clinical benefit and ESMO-Magnitude of Clinical Benefit Scale (ESMO-MCBS) scoring. ESMO Open. 2021 Apr 19;6(3):100117. doi: 10.1016/j.esmoop.2021.100117. Epub ahead of print. Access online here.

This Week’s Quick Bites:

  1. Chida K, et al.. A Low Tumor Mutational Burden and PTEN Mutations Are Predictors of a Negative Response to PD-1 Blockade in MSI-H/dMMR Gastrointestinal Tumors. Clin Cancer Res. 2021 Apr 29. doi: 10.1158/1078-0432.CCR-21-0401. Epub ahead of print. PMID: 33926917. Access online here.
  2. Siena S, et al. Trastuzumab deruxtecan (DS-8201) in patients with HER2-expressing metastatic colorectal cancer (DESTINY-CRC01): a multicentre, open-label, phase 2 trial. Lancet Oncol. 2021 May 4:S1470-2045(21)00086-3. doi: 10.1016/S1470-2045(21)00086-3. Epub ahead of print. PMID: 33961795. Access online here.
  3. Woitowich NC, et al. Gender Differences in Physician Use of Social Media for Professional Advancement. JAMA Netw Open. 2021;4(5):e219834. Access online here.
  4. Hall, P.S., et al. Efficacy of Reduced-Intensity Chemotherapy With Oxaliplatin and Capecitabine on Quality of Life and Cancer Control Among Older and Frail Patients With Advanced Gastroesophageal Cancer: The GO2 Phase 3 Randomized Clinical Trial. JAMA Oncol. Published online May 13, 2021. Access online here.
  5. Griggs, J.J., et al. Appropriate Systemic Therapy Dosing for Obese Adult Patients With Cancer: ASCO Guideline Update. DOI: 10.1200/JCO.21.00471 Journal of Clinical Oncology. Published online May 03, 2021. Access online here.
  6. Lubel, J.S., et al. Australian recommendations for the management of hepatocellular carcinoma: a consensus statement. MJA. Access online here.

Amazing Article of the Week:

  1. Gale, RP. Chernobyl at 35 Years: An Oncologist’s Perspective. The ASCO Post. Access online here.

Access Program Update: 

Information from Bayer re NUBEQA® Patient Access Program (pdf)

Final ARAMIS publication and Plain Language Summary

Other Episodes Mentioned:

The OJC Episode 32: When the Oncologist gets cancer


This Week’s Team:

Professor Eva Segelov

Eva Segelov

Professor Eva Segelov is a Medical Oncologist and is Director of Oncology at Monash University and Monash Health, Melbourne, Victoria, previously Senior Medical Oncologist at St Vincent’s Hospital, St Vincent’s Private Hospital and St Vincent’s Clinic and Associate Professor of Medicine, University of New South Wales.

Eva has an interest in academic clinical trials in GI and breast cancer and has been a member of the AGITG since 2003. She has clinical trials expertise, links with national and international trials groups, and extensive experience with adult medical education.

You can find Eva on Twitter here: @profevasegelov

Dr Craig Underhill

Craig Underhill

Dr Craig Underhill completed his Bachelor of Medicine and Surgery in 1987 at Melbourne University. He completed medical oncology training in Melbourne and worked as the Senior Clinical Research Registrar at Guy’s Hospital, London.

In 1998 arrived in Albury-Wodonga and established a medical oncology practice and clinical trials unit which has developed expertise and infrastructure to ensure the initiation of high quality trials. The research Unit lead by Dr Underhill has twice been awarded NSW Premier’s Award for Innovation in Cancer Clinical Trials, the inaugural award in 2009 and then again in 2012.

Dr Underhill chaired a working party that was instrumental in securing $65 million in federal funding for The Albury Wodonga Regional Cancer Centre which opened in September 2016.

Dr Underhill is the VCCC Regional Oncology Lead and advocates for the increased access to clinical trials for regional Victorians and leads the VCCC teletrials program.

You can find Craig on Twitter here: @CraigUnderhill

Professor Hans Prenen

Hans Prenen

Professor Hans Prenen is a medical oncologist and head of the phase 1 – early clinical trials unit at the Antwerp University Hospital in Belgium. He is a member of several scientific organisations, published many scientific oncology papers in prestigious journals and is regularly invited for lectures at national and international meetings.  His interests are clinical trials and translational research with a focus on digestive oncology.

You can find Hans on Twitter here: @HPrenen

 

Dr Kristi Milley

Dr Kristi Milley is an Early Career Researcher and science communicator focused on cancer in primary care clinical trials. Her research includes improving consumer engagement in cancer research and the role of social media. She is the National Manager of the Primary Care Collaborative Cancer Clinical Trials Group (PC4). PC4 is funded by Cancer Australia and has supported research that has attracted over $20 million in competitive funding for trials across the cancer continuum, from prevention to palliative care. Since 2017, Kristi has led a creative team who focus on supporting primary care researchers and promoting the important role primary care plays in cancer care. Kristi is also host of the podcast Research Round-up which dives deep into current cancer in primary care research with both Australian and international leaders in the field.

PC4’s Consumer Engagement Strategy that was designed based on learnings from this study. 

Rachael Babin

Rachael Babin is Editor-in-Chief of The Oncology Newsletter, Publisher of Oncology News Host of The Oncology Podcast and Producer of The Oncology Journal Club. For regular oncology updates for healthcare professionals, please subscribe to The Oncology Newsletter.

With thanks to Eva Segelov, Craig Underhill, Hans Prenen, Kristi Milley and Graham Knowles.

Connect with us on Twitter @OncologyNewsAus

Share.

About Author

The ONA Editor curates oncology news, views and reviews from Australia and around the world for our readers. In aggregated content, original sources will be acknowledged in the article footer.

Leave A Reply

This site uses Akismet to reduce spam. Learn how your comment data is processed.